GlassScriptPhysician profile
Ann C Janik
NPI 1134199862
$4,083.05
in general payments reported to CMS, 2019-2025
24 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.47 · 2022: $539 · 2023: $742 · 2024: $1,306 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.59 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $859.98 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $715.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $305.49 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $302.59 | 2022-2025 | |
| Leo Pharma INC. | $261.19 | 2022-2025 | Adbry |
| Ucb, INC. | $215.29 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $168.55 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $154.81 | 2022-2025 | |
| Pfizer INC. | $154.77 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $135.69 | 2022-2025 | Sotyktu |
| Incyte Corporation | $127.82 | 2022-2025 | Opzelura |
| Amgen INC. | $101.48 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $98.81 | 2023-2024 | Vtama |
| Lilly USA, LLC | $92.77 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.08 | 2021-2024 | Jublia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $58.33 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $56.12 | 2023-2024 | Ilumya |
| Almirall LLC | $48.98 | 2025 | Seysara |
| Verrica Pharmaceuticals INC. | $43.11 | 2025 | Ycanth |
| Journey Medical Corporation | $27.60 | 2024 | |
| Kyowa Kirin, INC. | $23.76 | 2024 | Poteligeo |
| Hill Dermaceuticals, INC. | $22.20 | 2025 | Tolak |
| Lnhc, INC | $18.09 | 2025 | Zelsuvmi |
| Organon LLC | $11.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Janik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.